Objectives:

1. Review the pathophysiology of uterine carcinosarcoma
2. Identify the unique needs of the patients affected by uterine carcinosarcoma
3. Review current strategies for treating uterine carcinosarcoma and discuss potential future directions

and

1. Understand biologics’ role in escalating health care expenditures in the U.S.
2. Compare and contrast the features of the small molecule-generic and biologic-biosimilar relationships and relevant regulation

3.   Evaluate barriers to biosimilar market penetration and individual prescribing